Tamtam Try Tamtam free
Teleflex logo

Teleflex account plan

Healthcare product provider

At a glance

Teleflex makes single-use medical devices for critical care and surgery; FY2025 continuing revenue $1,992.7 million, 2026 guide $2,256-2,276 million.

Teleflex Incorporated, based in Wayne, PA, designs, manufactures and supplies single-use medical devices for critical care and surgical procedures, sold to hospitals through a direct sales force and distributors; major plants are in the Czech Republic, Malaysia, Mexico and the U.S. FY2025 net revenues from continuing operations were $1,992.7 million (+17.2%), boosted by the acquired BIOTRONIK Vascular Intervention business, while the group posted a net loss of $905.6 million driven by impairments on businesses being sold. After selling OEM in August 2026 and with Acute Care and Interventional Urology under sale, it now runs three global units: Vascular, Interventional and Surgical. It employed approximately 15,500 people at December 31, 2025; Jason Weidman has been President and CEO since June 8, 2026.

Business units

Strategic priorities

Complete the transformation
Close the Acute Care and Interventional Urology sale, targeted by end of 2026 but possibly 2027 after an FTC second request, and finish integrating Interventional.
Simpler operating model
Move from a geographic matrix to three global business units, each owning its strategy, resources and results.
Raise the growth profile through innovation
R&D raised to close to 8% of revenue, with Freesolve resorbable magnesium scaffold (BIOMAG data due late 2027) and EZPLAZ, a U.S. opportunity of at least $200 million.
Return capital and cut debt
Plan of $1 billion of buybacks and $800 million of debt reduction from divestiture proceeds; net leverage about 1.4x in Q3 2026.
Margin step-up
Adjusted operating margin about 20.0% in 2026, approximating 23% in the first year after the Acute Care and IU close, with about $50 million of annual restructuring savings.

Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue from continuing operations was $567.8 million, up 0.2% reported and 3.0% on a pro forma adjusted constant currency basis. Gross margin rose to 65.0% from 51.5%, helped by the end of VI inventory step-up and a $25.3 million IEEPA tariff refund, and adjusted diluted EPS was $2.63 (vs $1.89). Net income was $927.4 million including the gain on the OEM sale. Teleflex kept its 2026 pro forma constant currency growth guidance at 3.5%-4.5%, cut GAAP revenue guidance to $2,256-2,276 million on FX and raised adjusted EPS guidance to $7.50-$7.75.

Investments and deals

BIOTRONIK Vascular Intervention acquisition
Acquired June 30, 2025 for a net €704.3 million ($825.2 million), adding $202.4 million of 2025 revenue.
OEM divestiture
Closed August 3, 2026: net cash proceeds of $1.5 billion ($1.25 billion after tax).
Share repurchases
4.6 million shares bought for $600.0 million in 2026 to the filing date, with $400.0 million left on the $1 billion authorization.
Restructuring plans
VI integration plan targeting $24-30 million of annual savings by end of 2028, and the Strategic Divestitures plan targeting $48-52 million by mid-2028.
New ERP
Ongoing development of a new ERP solution raised IT costs.

Challenges and risks

Slow VI integration
Order-to-cash, distributor and sales force transitions held Interventional back; open territories are down 63% from peak and new reps need about 6 months to become productive.
Tariffs
Tariff costs of a little over $30 million in 2026, with similar levels expected in 2027.
Divestiture timing
The Acute Care and IU sale faces an FTC second request and may slip into 2027, with stranded costs to remove.
GLP-1 impact on bariatric surgery
Reduced bariatric procedures led to a $100.0 million impairment on the Titan SGS asset group in 2025.
China procurement and sterilization rules
China volume-based procurement cuts prices, and EPA ethylene oxide emission standards affect contract sterilizers Teleflex depends on.

What leadership says

“a meaningful step-up in adjusted earnings per share”

Jason Weidman, President and CEO · On 2027, Q3 2026 earnings call, November 5, 2026

“this is absolutely not a product issue”

Jason Weidman, President and CEO · On the Interventional integration, Q2 2026 earnings call, August 6, 2026

“a more focused, agile and growth-oriented Teleflex”

Jason Weidman, President and CEO · Q3 2026 earnings call, November 5, 2026

“we're confident this transaction will be completed.”

Jason Weidman, President and CEO · On the Acute Care and IU sale, Q3 2026 earnings call, November 5, 2026

Where a supplier can help

Order-to-cash and distributor transitions
The VI integration challenge sits in ordering, distributor and consignment processes; supply chain, ERP and order management partners can help close it.
Sales force onboarding
Refilling territories with reps who need about 6 months to ramp creates demand for sales training, enablement and territory planning tools.
Stranded cost removal
The Strategic Divestitures restructuring plan targets $48-52 million of savings, favouring shared services, IT and process simplification vendors.
Clinical trial and R&D support
Higher R&D spend and the BIOMAG III U.S. pivotal trial call for CROs, clinical data and regulatory services.
Tariff and supply chain optimisation
Tariff mitigation through supply chain changes and more USMCA-compliant products needs sourcing, trade compliance and logistics expertise.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Teleflex?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Teleflex

What does Teleflex do?

Teleflex designs and manufactures single-use medical devices for critical care and surgical procedures, organised into Vascular, Interventional and Surgical units.

What is Teleflex's revenue?

FY2025 net revenues from continuing operations were $1,992.7 million; 2026 guidance is $2,256-2,276 million.

How many employees does Teleflex have?

Approximately 15,500 at December 31, 2025, before the divestitures.

Who leads Teleflex?

Jason Weidman has been President and CEO since June 8, 2026; John R. Deren is CFO and Andrew A. Krakauer is Chairman.

What is Teleflex's strategy?

Teleflex is divesting Acute Care, Interventional Urology and OEM to focus on three global units, raising R&D, simplifying its operating model and returning capital through buybacks and debt reduction.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)